Dual-phase 18F-FDG PET can predict lung adenocarcinoma outcome

03/31/2010 | HealthImaging.com

A study involving patients with histologically confirmed lung adenocarcinoma found that the change in maximal standardized uptake values between early and delayed 18F-FDG PET can be a strong singular predictor of patient outcome and aid in patient management. "Patients with more than 25 percent increase in SUVmax had a median survival of 15 months, compared with 39 months for those with less than 25 percent increase in SUVmax," the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations